Evidence map›Paper›PMID 12955501›Full record

ArticleMedical microbiology and immunology2004

Prospective study on nontuberculous mycobacteria in patients with and without cystic fibrosis.

Lorenz Leitritz, Matthias Griese, Andreas Roggenkamp, Anna Maria Geiger, Volker Fingerle, Jürgen Heesemann

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Medical microbiology and immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. Review
  4. Prevalence and drug resistance of mycobacteria in Turkish cystic fibrosis patients.Annals of clinical microbiology and antimicrobials · 2014
    Article
  5. Review
  6. The changing microbial epidemiology in cystic fibrosis.Clinical microbiology reviews · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lorenz LeitritzMax von Pettenkofer-Institut, Ludwig-Maximilians-Universität München, Pettenkoferstrasse 9a, 80336 München, Germany. lorenz.leitritz@mvp.med.uni-muenchen.de
Matthias Griese
Andreas Roggenkamp
Anna Maria Geiger
Volker Fingerle
Jürgen Heesemann

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent reports indicated an increase of nontuberculous mycobacteria (NTM) in cystic fibrosis (CF) patients. However, it is still a matter of discussion whether criteria for diagnosis of NTM pulmonary infection established by the American Thoracic Society (ATS) are applicable for CF patients. We determined incidence and prevalence of NTM in CF patients and non-CF patients without HIV infection, and validity of ATS criteria for CF patients. Over a period of 2 years, 1,251 respiratory samples were investigated for mycobacteria from 91 CF and 162 non-CF patients. For all patients with NTM recovery, we reviewed clinical charts and determined outcome for up to 2 years. Incidence and prevalence for repeated recovery of NTM were higher in CF patients, but not significantly. CF patients with repeated recovery of NTM met clinical and bacteriological ATS criteria, but radiographic criteria were not met. Treated CF patients showed favorable clinical outcomes, as opposed to untreated patients. We propose a modified definition for diagnosis and hence treatment of NTM pulmonary infection in CF patients.

Indexed as

AdolescentAdultChildChild, PreschoolCohort StudiesCross-Sectional StudiesCystic FibrosisFemaleHIV InfectionsHumansInfantMaleMiddle AgedMycobacteriumMycobacterium InfectionsProspective Studies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.